Innovative GX Florida , INC
Innovative GX Florida , INC was paid $325K by Medicaid between Jan 2018 and Jul 2024, across 96 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 33% of everything it billed.
BOCA RATON, FL 33431
Next to other Clinical Medical Laboratory providers in Florida
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68 | $0.00 | |
| 2019 | 14,512 | $28K | |
| 2020 | 10,745 | $39K | |
| 2021 | 7,284 | $101K | |
| 2022 | 2,169 | $45K | |
| 2023 | 6,043 | $89K | |
| 2024incomplete | 1,623 | $22K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 33% | 2,244 | 1,754 | $108K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 22% | 2,709 | 700 | $72K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.1% | 1,022 | 203 | $26K |
| 87481 | 4.6% | 745 | 547 | $15K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 3,590 | 2,714 | $7K |
| 80053 | Comprehensive metabolic panel | 2.2% | 3,352 | 2,553 | $7K |
| 87529 | 1.6% | 402 | 299 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 1,064 | 777 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.5% | 2,170 | 1,543 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 2,168 | 1,640 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.2% | 268 | 186 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 545 | 470 | $4K |
84 more codes
| 81380 | 1.1% | 47 | $3K | |
| 87641 | 1.0% | 565 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 100 | $3K |
| 87500 | <1% | 450 | $3K | |
| 81249 | <1% | 23 | $2K | |
| 80061 | Lipid panel | <1% | 2,687 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 334 | $2K |
| 87653 | <1% | 286 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 315 | $2K |
| 81400 | <1% | 82 | $2K | |
| 87070 | <1% | 1,100 | $2K | |
| 87563 | <1% | 236 | $2K | |
| 82607 | <1% | 629 | $2K | |
| 87640 | <1% | 512 | $2K | |
| 84439 | <1% | 957 | $1K | |
| 84403 | <1% | 255 | $1K | |
| 86328 | <1% | 58 | $1K | |
| 84402 | <1% | 209 | $1K | |
| 86769 | <1% | 116 | $1K | |
| 87631 | <1% | 102 | $1K | |
| 84270 | <1% | 200 | $1K | |
| 84153 | <1% | 340 | $975.18 | |
| 82670 | <1% | 126 | $947.01 | |
| 80050 | General health panel | <1% | 470 | $943.46 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,625 | $929.11 |
| 87186 | <1% | 928 | $885.31 | |
| 87077 | <1% | 876 | $878.73 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 975 | $872.17 |
| 81001 | <1% | 986 | $866.06 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 234 | $830.24 |
| 84481 | <1% | 284 | $793.50 | |
| 82627 | <1% | 87 | $709.16 | |
| 84436 | <1% | 1,072 | $647.89 | |
| 82746 | <1% | 209 | $635.66 | |
| 82728 | <1% | 253 | $631.00 | |
| 87551 | <1% | 28 | $586.82 | |
| 81291 | <1% | 82 | $549.44 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 130 | $544.95 |
| 81240 | <1% | 82 | $536.91 | |
| 81241 | <1% | 82 | $536.91 | |
| 86696 | <1% | 101 | $491.63 | |
| 85652 | <1% | 398 | $471.32 | |
| 82533 | <1% | 47 | $463.19 | |
| 83001 | <1% | 88 | $419.58 | |
| 83002 | <1% | 96 | $418.14 | |
| APT16 | <1% | 31 | $411.99 | |
| APT17 | <1% | 32 | $411.99 | |
| 84702 | <1% | 173 | $408.91 | |
| 81226 | <1% | 15 | $360.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 167 | $328.93 |
| 83718 | <1% | 30 | $309.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14 | $303.32 |
| 83735 | <1% | 157 | $273.89 | |
| 84144 | <1% | 51 | $265.03 | |
| 84479 | <1% | 830 | $231.64 | |
| 83550 | <1% | 169 | $231.43 | |
| 82043 | <1% | 231 | $222.82 | |
| 83540 | <1% | 187 | $219.83 | |
| 86592 | <1% | 184 | $218.43 | |
| 87581 | <1% | 102 | $182.88 | |
| 87625 | <1% | 37 | $180.34 | |
| 82172 | <1% | 26 | $135.24 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 35 | $90.96 |
| 87340 | <1% | 34 | $89.62 | |
| 82040 | <1% | 252 | $87.12 | |
| 84146 | <1% | 28 | $73.11 | |
| 86141 | <1% | 24 | $65.40 | |
| 80076 | <1% | 19 | $64.24 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 40 | $61.16 |
| 87102 | <1% | 71 | $60.24 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 34 | $53.44 |
| 83090 | <1% | 26 | $42.79 | |
| 82570 | <1% | 18 | $41.36 | |
| 86762 | <1% | 18 | $35.12 | |
| 87205 | <1% | 44 | $34.12 | |
| 87106 | <1% | 20 | $25.24 | |
| 80164 | <1% | 12 | $20.42 | |
| 85610 | <1% | 17 | $14.84 | |
| 87206 | <1% | 12 | $9.09 | |
| 84550 | <1% | 82 | $6.25 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 14 | $0.79 |
| 81223 | 0% | 23 | $0.00 | |
| 81373 | 0% | 31 | $0.00 | |
| 82248 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.